Drug Trial Radar · NCT04136184
NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
Last checked: Nov 20, 2026Latest source record: Dec 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
168
Actual
Start
Dec 11, 2019
Primary completion
Apr 11, 2023
Study completion Jul 12, 2023
Sponsor
- Lead sponsor
- Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
- Sponsor type
- Industry
- First posted
- Oct 23, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 82 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of this study was to evaluate the efficacy of eplontersen as compared with the historical control of the placebo cohort in the NEURO-TTR trial (NCT01737398/2012-001831-30), in subjects with hereditary transthyretin-mediated amyloidosis polyneuropathy (hATTR-PN). For more information, please visit http://www.neuro-ttransform.com/.
Conditions
- Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
Interventions
InotersenDrug
Inotersen by subcutaneous injection
EplontersenDrug
Eplontersen by subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Modified Neuropathy Impairment Score Plus 7 (mNIS+7) at Week 66Time frame: Baseline, Week 66
- Change From Baseline in the Norfolk Quality of Life Diabetic Neuropathy (QoL-DN) Questionnaire at Week 66Time frame: Baseline, Week 66
- Percent Change From Baseline in Serum TTR Concentration at Week 65Time frame: Baseline, Week 65
- Percent Change From Baseline in Serum TTR Concentration at Week 35Time frame: Baseline, Week 35
- Change From Baseline in Modified Neuropathy Impairment Score Plus 7 (mNIS+7) at Week 35Time frame: Baseline, Week 35
Locations
45 sites in 16 countries. Site status is shown where the registry gives one.
Mayo Clinic - Arizona
Scottsdale, Arizona
Mayo Clinic - Jacksonville
Jacksonville, Florida
Indiana University School of Medicine - Indianapolis
Indianapolis, Indiana
University of Kansas Medical Center
Kansas City, Kansas
Johns Hopkins University Neurology Research Office
Baltimore, Maryland
Boston University School of Medicine
Boston, Massachusetts
Mayo Clinic - Rochester
Rochester, Minnesota
The Neurological Institute of New York
New York, New York
University of North Carolina Hospitals - Neurology Clinic
Chapel Hill, North Carolina
Oregon Health and Science University
Portland, Oregon
Penn Presbyterian Medical Center
Philadelphia, Pennsylvania
University of Washington Medical Center
Seattle, Washington
STAT Research
Buenos Aires, Argentina
Instituto Fleni
Buenos Aires, Argentina
Hospital Italiano de Buenos Aires
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Hospital El Cruce
San Juan Bautista, Buenos Aires, Argentina
Perron Institute for Neurological and Translational Science
Nedlands, Western Australia, Australia
Universidade Estadual de Campinas
Campinas, Brazil
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto
Ribeirão Preto, Brazil
Hospital Universitário Clementino Fraga Filho
Rio de Janeiro, Brazil
Associação de Assistência à Criança Deficiente - Unidade Lar Escola
São Paulo, Brazil
Instituto de Neurologia de Curitiba
Curitiba, Paraná, Brazil
Toronto General Hospital
Toronto, Ontario, Canada
The Cyprus Institute of Neurology and Genetics
Égkomi, Cyprus
Hôpital de la Timone
Marseille, France
Centre Hospitalier Universitaire de Toulouse
Toulouse, Haute-Garonne, France
Hôpital Bicêtre
Le Kremlin-Bicêtre, Île-de-France Region, France
Universitätsklinikum Heidelberg
Heidelberg, Germany
Universitätsklinikum Würzburg
Würzburg, Bavaria, Germany
University General Hospital of Heraklion (PAGNI)
Heraklion, Crete, Greece
Azienda Ospedaliera Universitaria Policlinico Gaetano Martino
Messina, Italy
Fondazione IRCCS Istituto Neurologico Carlo Besta
Milan, Italy
Fondazione IRCCS Policlinico San Matteo
Pavia, Italy
Fondazione Policlinico Universitario Agostino Gemelli
Roma, Italy
Auckland City Hospital
Grafton, Auckland, New Zealand
Centro Hospitalar Universitário Lisboa Norte - Hospital De Santa Maria
Lisbon, Portugal
Centro Hospitalar Universitário do Porto - Hospital Geral de Santo Antonio
Porto, Portugal
Hospital Clínico San Carlos
Madrid, Spain
Hospital Son Llàtzer
Palma de Mallorca, Balearic Islands, Spain
Norrlands Universitetssjukhus
Umeå, Sweden
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.